Cross-presentation of synthetic long peptides by human dendritic cells: A process dependent on ERAD component p97/VCP but not sec61 and/or Derlin-1

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Ménager, Jérémie ^a,b,c   Ebstein, Frédéric ^d   Oger, Romain ^a,b,c   Hulin, Philippe ^a,c   Nedellec, Steven ^a,c   Duverger, Eric ^e   Lehmann, Andrea ^d   Kloetzel, Peter Michael ^d   Jotereau, Francine ^a,b,c   Guilloux, Yannick ^a,b,c  

^a Team 12   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CNRS   (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITÉ D'ORLÉANS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL PROTEIN; DERLIN 1; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION MACHINERY PROTEIN; MELAN A; MELAN A[26-35]; MEMBRANE PROTEIN; PEPTIDE; POLYPEPTIDE; PROTEIN P97; SEC61 PROTEIN; SYNTHETIC LONG PEPTIDE; SYNTHETIC LONG PEPTIDE[16-40]; UNCLASSIFIED DRUG;

ARTICLE; CELL COMPOSITION; CELL KINETICS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DRUG DETERMINATION; DRUG SYNTHESIS; ENDOSOME; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LYSOSOME; MOLECULAR DYNAMICS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATASES; ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; CELL CYCLE PROTEINS; CROSS-PRIMING; DENDRITIC CELLS; ENDOCYTOSIS; ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION; ENDOSOMES; HUMANS; KINETICS; LYSOSOMES; MART-1 ANTIGEN; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT;

EID: 84896125442     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089897     Document Type: Article

References (51)

1. Coley WB (1928) End Results in Hodgkin's Disease and Lymphosarcoma Treated by the Mixed Toxins of Erysipelas and Bacillus Prodigiosus, Alone or Combined with Radiation. Ann Surg 88: 641-667.
2. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-281.
3. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337-365. (Pubitemid 24140418)
4. Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
5. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449: 419-426. (Pubitemid 47509552)
6. Bevan MJ (2006) Cross-priming. Nat Immunol 7: 363-365.
7. Ackerman AL, Cresswell P (2004) Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5: 678-684. (Pubitemid 39023296)
8. Joffre OP, Segura E, Savina A, Amigorena S (2012) Cross-presentation by dendritic cells. Nature reviews Immunology 12: 557-569.
9. Burgdorf S, Kurts C (2008) Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol 20: 89-95.
10. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C (2008) Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 9: 558-566. (Pubitemid 351560525)
11. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, et al. (2003) ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425: 397-402. (Pubitemid 37187268)
12. van Montfoort N, Camps MG, Khan S, Filippov DV, Weterings JJ, et al. (2009) Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A 106: 6730-6735.
13. Baxevanis CN, Perez SA, Papamichail M (2009) Cancer immunotherapy. Crit Rev Clin Lab Sci 46: 167-189.
14. Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109: 1519-1526. (Pubitemid 34663511)
15. Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8: 351-360. (Pubitemid 351589701)
16. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, et al. (2008) Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 38: 1033-1042.
17. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, et al. (2007) CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179: 5033-5040.
18. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, et al. (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361: 1838-1847.
19. Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, et al. (2009) Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 125: 2104-2113.
20. Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, et al. (2009) Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 15: 1086-1095.
21. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, et al. (2008) Induction of tumor-specific CD4 + and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14: 178-187. (Pubitemid 351377994)
22. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, et al. (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160: 1750-1758. (Pubitemid 28110836)
23. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, et al. (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180: 347-352. (Pubitemid 24181083)
24. Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, et al. (1995) Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. The Journal of experimental medicine 181: 363-368.
25. Chauvin JM, Larrieu P, Sarrabayrouse G, Prevost-Blondel A, Lengagne R, et al. (2012) HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells. J Immunol 188: 2102-2110.
26. Coulais D, Panterne C, Fonteneau JF, Gregoire M (2012) Purification of circulating plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic beads. Cytotherapy 14: 887-896.
27. Vignard V, Lemercier B, Lim A, Pandolfino MC, Guilloux Y, et al. (2005) Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol 175: 4797-4805. (Pubitemid 41362023)
28. Bolte S, Cordelieres FP (2006) A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224: 213-232. (Pubitemid 46010930)
29. Faure F, Mantegazza A, Sadaka C, Sedlik C, Jotereau F, et al. (2009) Long-lasting cross-presentation of tumor antigen in human DC. Eur J Immunol 39: 380-390.
30. Segura E, Villadangos JA (2011) A modular and combinatorial view of the antigen cross-presentation pathway in dendritic cells. Traffic 12: 1677-1685.
31. Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, et al. (2010) Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A 107: 18599-18604.
32. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, et al. (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the National Academy of Sciences of the United States of America 96: 10403-10408. (Pubitemid 29422570)
33. Groettrup M, Standera S, Stohwasser R, Kloetzel PM (1997) The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proceedings of the National Academy of Sciences of the United States of America 94: 8970-8975. (Pubitemid 27357766)
34. Ackerman AL, Giodini A, Cresswell P (2006) A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 25: 607-617. (Pubitemid 44529035)
35. Hotta C, Fujimaki H, Yoshinari M, Nakazawa M, Minami M (2006) The delivery of an antigen from the endocytic compartment into the cytosol for crosspresentation is restricted to early immature dendritic cells. Immunology 117: 97-107.
36. Zehner M, Chasan AI, Schuette V, Embgenbroich M, Quast T, et al. (2011) Mannose receptor polyubiquitination regulates endosomal recruitment of p97 and cytosolic antigen translocation for cross-presentation. Proc Natl Acad Sci U S A 108: 9933-9938.
37. Claessen JH, Kundrat L, Ploegh HL (2012) Protein quality control in the ER: balancing the ubiquitin checkbook. Trends in cell biology 22: 22-32.
38. Liu Y, Ye Y (2011) Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy. Cell research 21: 867-883.
39. Ramanathan HN, Ye Y (2012) The p97 ATPase associates with EEA1 to regulate the size of early endosomes. Cell Res 22: 346-359.
40. Crespo MI, Zacca ER, Nunez NG, Ranocchia RP, Maccioni M, et al. (2013) TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8alpha+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface. Journal of immunology 190: 948-960.
41. Imai J, Hasegawa H, Maruya M, Koyasu S, Yahara I (2005) Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells. International immunology 17: 45-53.
42. Fonteneau JF, Kavanagh DG, Lirvall M, Sanders C, Cover TL, et al. (2003) Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood 102: 4448-4455. (Pubitemid 37494109)
43. Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, et al. (2013) Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. European journal of immunology 43: 2554-2565.
44. Pillay CS, Elliott E, Dennison C (2002) Endolysosomal proteolysis and its regulation. Biochem J 363: 417-429. (Pubitemid 34526362)
45. Quakkelaar ED, Melief CJ (2012) Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol 114: 77-106.
46. Giodini A, Rahner C, Cresswell P (2009) Receptor-mediated phagocytosis elicits cross-presentation in nonprofessional antigen-presenting cells. Proceedings of the National Academy of Sciences of the United States of America 106: 3324-3329.
47. Needham PG, Brodsky JL (2013) How early studies on secreted and membrane protein quality control gave rise to the ER associated degradation (ERAD) pathway: The early history of ERAD. Biochimica et biophysica acta.
48. Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, et al. (2000) Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12: 107-117. (Pubitemid 30069219)
49. Chapatte L, Ayyoub M, Morel S, Peitrequin AL, Levy N, et al. (2006) Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. Cancer Res 66: 5461-5468. (Pubitemid 43844974)
50. Kessler JH, Khan S, Seifert U, Le Gall S, Chow KM, et al. (2011) Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol 12: 45-53.
51. Lattanzi L, Rozera C, Marescotti D, D'Agostino G, Santodonato L, et al. (2011) IFN-alpha boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology 216: 537-547.